Oral mucositis induced by conventional cytotoxic cancer therapies is a common and
significant clinical problem in oncology. Mucositis symptoms, which include severe pain …

Herpes simplex viruses (HSV), the causative agents of recurrent orofacial and anogenital
infections, can cause significant morbidity and mortality in both immunocompetent and …

Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among
patients with malignancies and manifest particularly as herpes simplex stomatitis in patients …

Background Oral mucositis is a serious and debilitating side effect of conditioning regimens
for hematopoietic stem cell transplant (HSCT). Through HSCT, the homeostasis in the oral …

Oral Mucositis (OM) is among the most common and dreaded toxicities of cancer therapy. It
occurs in almost all patients who receive radiation therapy in which areas of oral and …

The use of genotypic resistance testing of herpes simplex virus types 1 and 2 (HSV-1 and
HSV-2) is increasing because the rapid availability of results significantly improves the …

Hematopoietic stem cell transplantation (HSCT) is widely used as a potentially curative
treatment for patients with various hematological malignancies, bone marrow failure …

With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in
oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis …

Abstract Characterization of the role of oral microbiome in cancer therapy-induced oral
mucositis (CTOM) is critical in preventing the clinically deleterious effects on patients' health …

Herpes simplex virus (HSV) infections in allogeneic haematopoietic stem cell transplantation
(HSCT) recipients pose significant challenges, with higher incidence, severity, and risk of …